Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study

doi:10.21037/atm-22-988

	Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study
	Zhang, Xi 1; Lian, Xue-Mei 2; Gu, Xiao-Fen 3; Liu, Yin 4; Feng, Chang-Yan 5; Li, Li 6; Xu, Hui-Fang 4; Du, Jing-Chang 7; Zhao, Yu-Qian 8; Ma, Li 9
刊名	ANNALS OF TRANSLATIONAL MEDICINE
	2022-03-16
关键词	Colorectal cancer (CRC) biomarker RAS BRAF microsatellite instability (MSI)
ISSN号	2305-5839
DOI	10.21037/atm-22-988
通讯作者	Zhang, Shao-Kai(shaokaizhang@126.com) ; Shi, Ji-Hai(sjh@btmc.edu.cn) ; Qiao, You-Lin(qiaoy@cicams.ac.cn)
英文摘要	Background: Biomarkers are a key tool in early detection, prognostication, survival, and predicting treatment response of colorectal cancer (CRC). However, little is known about biomarker testing for CRC patients in real-life clinical practice in China. This study aimed to address the usage of biomarker testing and analyze factors related to its acceptance among Chinese patients with advanced CRC. Methods: A multicenter, cross-sectional, hospital-based clinical epidemiology study was conducted from March 2020 to March 2021. Nineteen hospitals were selected in seven geographical regions of China using stratified, multistage, nonrandomized cluster sampling. Data on demographics and clinical characteristics of each eligible CRC patient in stage III or IV diseases were recorded based on the patients' self-reporting and/ or medical records. In addition, information on whether biomarker testing [RAS, BRAF, and microsatellite instability (MSI)] was performed, the results and timing for performing biomarker testing, and the reasons for refusing biomarker testing were also recorded. Univariate and multivariate logistic regression were conducted to explore the potential factors of biomarker testing. Results: A total of 4,526 patients were enrolled in the study, of whom 41.4%, 36.1%, and 28.2% underwent RAS, BRAF, and MSI testing, respectively. RAS, BRAF, and high-level MSI (MSI-high) mutation rates in Chinese patients with advanced CRC were 37.0%, 9.9%, and 8.1%, respectively. The logistic regression analysis revealed that the treating hospital, age at diagnosis, education, family income, tumor site, history of chemotherapy and radiotherapy, and metastases were dependent factors affecting the utilization of biomarker testing in advanced CRC in China (P<0.005). Conclusions: The biomarker testing rate, especially MSI testing, is less prevalent in clinical practice for patients with advanced CRC in China. Our findings may guide the formulation of biomarker testing of CRC strategies in China and other low-income countries.
资助项目	Beijing Love Book Cancer Foundation ; Merck Serono Co., Ltd.
WOS关键词	BRAF MUTATION ; MICROSATELLITE INSTABILITY ; 1ST-LINE TREATMENT ; POOLED ANALYSIS ; RAS MUTATIONS ; K-RAS ; CETUXIMAB ; SURVIVAL ; CHEMOTHERAPY ; POPULATION
WOS研究方向	Oncology ; Research & Experimental Medicine
语种	英语
出版者	AME PUBL CO
WOS记录号	WOS:000779715100001
资助机构	Beijing Love Book Cancer Foundation ; Merck Serono Co., Ltd.
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/128689]
专题	中国科学院合肥物质科学研究院
通讯作者	Zhang, Shao-Kai; Shi, Ji-Hai; Qiao, You-Lin
作者单位	1.Peking Univ Canc Hosp & Inst, Beijing Off Canc Prevent & Control, Minist Educ Beijing, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China 2.Chongqing Med Univ, Sch Publ Hlth & Management, Chongqing, Peoples R China 3.Xinjiang Med Univ, Dept Student Affairs, Affiliated Tumor Hosp, Urumqi, Peoples R China 4.Zhengzhou Univ, Henan Int Joint Lab Canc Prevent, Henan Engn Res Ctr Canc Prevent & Control, Dept Canc Epidemiol,Affiliated Canc Hosp,Henan Ca, 127 Dongming Rd, Zhengzhou 450008, Peoples R China 5.Chongqing Univ Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis &, Chongqing, Peoples R China 6.Jinan Univ, Affiliated Hosp 1, Dept Clin Res, Guangzhou, Peoples R China 7.Chengdu Med Coll, Sch Publ Hlth, Chengdu, Peoples R China 8.Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med, Chengdu, Peoples R China 9.Dalian Med Univ, Publ Hlth Sch, Dalian, Peoples R China 10.China Med Univ, Liaoning Canc Hosp & Inst, Liaoning Off Canc Control & Res, Canc Hosp, Shenyang, Peoples R China
推荐引用方式 GB/T 7714	Zhang, Xi,Lian, Xue-Mei,Gu, Xiao-Fen,et al. Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study[J]. ANNALS OF TRANSLATIONAL MEDICINE,2022.
APA	Zhang, Xi.,Lian, Xue-Mei.,Gu, Xiao-Fen.,Liu, Yin.,Feng, Chang-Yan.,...&Qiao, You-Lin.(2022).Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study.ANNALS OF TRANSLATIONAL MEDICINE.
MLA	Zhang, Xi,et al."Utilization of genetic biomarkers testing and its associated factors in advanced colorectal cancer patients in China: a nationwide multicenter clinical epidemiological study".ANNALS OF TRANSLATIONAL MEDICINE (2022).